Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Hepatocellular carcinoma, drawn from the whole corpus: 150 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Liver function limits therapy.
Surveillance uptake in cirrhosis is poor.
Background: Alpha-fetoprotein (AFP). Also on OnCo: Symptoms and red flags · Early detection roadmap.
No predictive biomarker chooses among the three first-line immunotherapy regimens; PD-L1, TMB and viral aetiology are weak.
Second-line therapy after immunotherapy failure is extrapolated from the sorafenib era; no dedicated phase 3 has read out.
TACE combinations prolong PFS but not (yet) OS; sequencing local and systemic therapy is unresolved.
Adjuvant therapy after curative resection remains unproven; recurrence is ~70% at five years.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Surveillance uptake is below 25% and ultrasound misses early tumours in obese, steatotic livers; MASLD-HCC often arises without cirrhosis.
Background: Alpha-fetoprotein (AFP). Also on OnCo: Symptoms and red flags · Early detection roadmap.
Immunotherapy in transplant candidates risks rejection; safe washout intervals are undefined.
Child-Pugh B patients are excluded from almost every trial yet make up a large share of real-world patients.
Global inequity: most cases occur in Asia and Africa, where HBV vaccination, HCV treatment and systemic therapy access are uneven.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 62 changes by month →When this page itself was last checked or edited.
Third CRL, again cGMP
Resubmission accepted; PDUFA 23 July 2026
PFS HR ~0.
A milestone in how this cancer is treated.
Second CRL